Although androgen-deprivation therapy is the standard therapy for advanced and metastatic prostate cancer, this treatment is only palliative.
Prostate cancer recurs then grows despite low circulating testicular androgens, using several mechanisms that remain dependent on androgen-receptor signaling in most cases. This article reviews the diversity of mechanisms used for growth by castration-recurrent prostate cancer.
Written by:
Azzouni F, Mohler J. Are you the author?
Department of Urology, Roswell Park Cancer Institute, Elm and Carlton streets, Buffalo, NY 14263, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):435-52.
doi: 10.1016/j.ucl.2012.07.002
PubMed Abstract
PMID: 23084522
UroToday.com Prostate Cancer Section
